Sagimet Biosciences price to book ratio SGMT

Market value divided by the book value of the company's net assets, since 2023.

Today, Oct 23, 2026: 2.3×
3-year median: 1.5×
Against its 3-year history: 86th; percentile: 0 is its lowest day, 100 its highest
3-year range: 0.4× to 5.5×
Peer median: 2.3×

Sagimet Biosciences' price to book ratio is 2.3× as of Oct 23, 2026.

That is above its 3-year median of 1.5×, higher than on 86% of days in the last 3 years.

Over that time it ranged from 0.4× in Sep 2024 to 5.5× in Aug 2026.

The median for 10 large drugmakers of a similar size is 2.3×.

Price to book ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	2.3×	1.4×	5.5×
2025	1.6×	0.4×	2.4×
2024	0.9×	0.4×	2.3×
2023	1.2×	0.6×	1.4×

Against its peers

Companies in Drug Manufacturers - General nearest Sagimet Biosciences' size, closest first, today.

Company	Price to book ratio
SGMTSagimet Biosciences	2.3×
ZVRAZevra Therapeutics	2.7×
CRMDCorMedix	1.3×
IRWDIronwood Pharmaceuticals	n/m
PBYIPuma Biotechnology	4.1×
ARVNArvinas	0.8×
COLLCollegium Pharmaceutical	2.4×
ABUSArbutus Biopharma	3.2×
AMPHAmphastar Pharmaceuticals	1.4×
OMEROmeros	n/m
PCRXPacira BioSciences	2.2×
Peer median	2.3×

What the price to book ratio tells you

Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.

Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.

More on Sagimet Biosciences

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.